Lilly Announces Positive Top-Line Results for Taltz® (ixekizumab) vs. Humira® (adalimumab) in a Head-to-Head (SPIRIT-H2H) Superiority Study in Patients with Active Psoriatic Arthritis
Register to receive a free Global Immunology Drugs Market Report Suite 2018-2024 report synopsis and brochure Eli Lilly and Company announced Taltz® (ixekizumab) met the primary and all major sec...Read More
